Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
FAIL · Does not pass the screen
23.89 USD
At the last full screen 2026-09-15
Screened 2026-09-15 · the tape above runs as of 23:00 UTC · 20 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 23.89 against the desk's fair-value range, base estimate 40.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price23.89 USD
Fair value40.00
Ethical score70.0/100
Our investment reviews on this name
2026-09-15Read Markdown25.47-6.2% to today ✓
2026-08-14Read Markup27.07-11.7% to today
2026-07-02Read Distribution30.94-22.8% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Tango Therapeutics, Inc. holds its Markdown at $23.89. Elevated stress, defensive posture warranted, held for 20 days.
As held on the ledger · 2026-09-15
Phase
Markdown · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 20 days
Price at the screen
$23.89
Valuation
N/A trailing · -14.18 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.12
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
8.42%
Below 33%
Interest-bearing debt is just 8.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
57.90%
Below 33%
Interest-bearing cash and securities are 57.9% of assets, above the one-third limit.
Fail
Receivables
28.16%
Below 49%
Money owed to the company is 28.2% of assets, under the 49% limit.
Pass
Revenue purity
9.02%
Below 5%
9.0% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-15 screen. The gold marker is the market price at the same screen. A 67.4% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Strong Buy. The average target sits +67% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-15 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cancer drug hunters face brutal odds here
Finding the right drug for the right cancer patient is like searching for a needle in a haystack that keeps moving. Tango is chasing that goal with its PRMT5 inhibitors aimed at defined groups with unmet need. Twelve analysts rate the shares strong buy with a median target of forty dollars, matching our fair value and clearing the ethical screen, yet the opportunity rating stays at none.
The numbers tell a harsher story. Forward earnings sit at negative eighteen point eight times, profit margins run at negative one hundred eighty eight per cent, and return on equity is negative thirty eight per cent. An unknown moat in a field where most candidates fail clinical trials leaves little room for error.
High cash burn and repeated dilution sit alongside execution risk that is typical for early stage oncology names. Currency and regulatory shifts can wipe out years of work overnight. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TNGX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-15Markdown · changed$25.47-5.9%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 56% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 542%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (10 analysts) rates it strong buy, with a mean price target of $32.
2026-08-14Markup · changed$27.07-12.5%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 12.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 56% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 542%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (10 analysts) rates it strong buy, with a mean price target of $32.
2026-07-18Distribution$30.94+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 56% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 542%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (10 analysts) rates it strong buy, with a mean price target of $32.
2026-07-03Distribution$30.94+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Distribution$30.94Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
